Brokerages Set Omeros Co. (NASDAQ:OMER) Target Price at $22.50

Shares of Omeros Co. (NASDAQ:OMER) have earned an average rating of “Moderate Buy” from the five ratings firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $22.50.

A number of equities analysts have commented on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a report on Tuesday. D. Boral Capital reissued a “buy” rating and set a $36.00 target price on shares of Omeros in a research report on Tuesday. Finally, StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research note on Tuesday.

Omeros Trading Down 4.1 %

Shares of NASDAQ:OMER opened at $7.06 on Wednesday. The company has a market capitalization of $409.93 million, a PE ratio of -3.06 and a beta of 2.35. Omeros has a 12-month low of $2.97 and a 12-month high of $13.60. The business’s fifty day simple moving average is $8.56 and its 200-day simple moving average is $7.63.

Hedge Funds Weigh In On Omeros

Hedge funds have recently modified their holdings of the stock. Truvestments Capital LLC grew its position in Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 1,972 shares during the period. Quantbot Technologies LP purchased a new stake in shares of Omeros during the fourth quarter valued at $46,000. BNP Paribas Financial Markets increased its position in shares of Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 7,016 shares during the period. Finally, Picton Mahoney Asset Management raised its stake in Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 4,404 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.